May 31, 2017 / 5:07 AM / 3 months ago

BRIEF-Aurobindo Pharma gets FDA nod for generic ADHD drug

May 31 (Reuters) - Aurobindo Pharma Ltd:

* Says Aurobindo Pharma receives USFDA approval for atomoxetine capsules

* Atomoxetine capsules are indicated for the treatment of attention-deficit/hyperactivity disorder Source text: bit.ly/2qzGo83 Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below